SignalXSignalX

TRDA Entrada Therapeutics, Inc.

8-K Current Report
Filed: February 26, 2026
Health Care
Pharmaceutical Preparations
Entrada Therapeutics, Inc. Overview

Entrada Therapeutics, Inc. (TRDA) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

  • Item 2.02: Results of Operations and Financial Condition

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

  • • Q4/full-year 2025 earnings press release issued Feb 26, 2026 — full financial details in Exhibit 99.1
  • • CEO Dipal Doshi signed filing, confirming current leadership in place at Entrada Therapeutics (TRDA)

Get deeper insights on Entrada Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.